|
Market Closed -
Nasdaq
04:00:00 18/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 515.55 USD | +1.94% |
|
-1.60% | +13.72% |
| 08-12 | Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says | MT |
| 08-11 | Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 563.12 | +9.23% | 25 | ||||||
| 1,310.9 | +10.8% | 28 | ||||||
| 272.5 | +3.86% | 22 | ||||||
| 276.41 | +10.42% | 29 | ||||||
| 370.31 | +3.99% | 18 | ||||||
| 154.18 | +1.19% | 21 | ||||||
| 211.88 | +35.21% | 22 | ||||||
| 387.07 | -7.7% | 29 | ||||||
| 313.7 | +7.29% | 24 | ||||||
| 157.41 | +13.31% | 27 | ||||||
| 28.61 | +6.46% | 26 | ||||||
| 66.21 | +2.44% | 24 | ||||||
| 94.28 | +22.98% | 23 | ||||||
| 21.61 | +16.73% | 20 | ||||||
| 9,426.67 | +37.33% | 15 | ||||||
| 6,450.19 | +17% | 16 | ||||||
| 56.92 | +18.82% | 18 | ||||||
| 79.25 | +49.9% | 16 | ||||||
| 41.4 | +13.55% | 10 | ||||||
| 4.208 | +20.17% | 17 | ||||||
| Average | 1,014.34 | +14.65% | 22 | ||||||
| Weighted average by Cap. | 705.97 | +10.11% | 24 |
- Stock Market
- Stocks
- VRTX Stock
- Sector Vertex Pharmaceuticals Incorporated
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
